Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
- 1Merck Sharp & Dohme LLC, A subsidiary of Merck & Co., Inc., Rahway, NJ USA
- 2Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199 USA
Abstract
Background and Objectives: Indolent non-Hodgkin’s lymphomas (NHL) are associated with relapses necessitating recurrent treatment and lifelong care. However, contemporary real-world evidence of the disease burden among patients with indolent NHLs remains limited. This study describes treatment patterns, healthcare resource use (HRU), and costs among patients with follicular lymphoma (FL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL) in the USA.
Methods: Adults with newly diagnosed FL, WM, and MZL were identified in claims data (October 2015−June 2021). The study period spanned from the index date (first observed diagnosis code) until end of continuous enrollment or data availability. Treatment patterns were described during the study period by lines of therapy (LOTs). HRU and costs per-patient-per-month (PPPM) were described overall and by LOTs.
Results: This study included 2805 patients with FL, 791 with WM, and 2207 with MZL with a median follow-up of > 20 months each. Bendamustine-based therapies and rituximab monotherapy were most common. In later lines, bendamustine-based therapies declined while rituximab monotherapy and ibrutinib-based therapies increased. Mean all-cause total costs were US $12,402, US $8445, and US $9580 PPPM for patients with FL, WM, and MZL, respectively. Disease-related medical costs constituted > 50% of all-cause total costs, with most hospitalization costs being disease-related. In FL, HRU and costs tended to increase by LOT, driven by FL-related hospitalizations. Trends in HRU and costs across LOTs were less clear for WM and MZL.
Conclusions: Our study suggests that indolent NHLs are associated with a significant economic burden that tends to increase across LOTs in FL, highlighting the need for better therapeutic options.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40261-026-01592-6.
Related
- The Challenges Associated with the Diagnosis and Treatment for Aplastic Anemia Concurrent with Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia
- Relapsed Waldenström macroglobulinemia presenting as bilateral parotid gland enlargement with multiple cystic lesions : A case report
- Waldenström macroglobulinemia presenting with lumbar vertebral fracture as the initial symptom: a rare case report and literature review
- Severe Aplastic Anemia Concurrent with Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia
- UMA RARA ASSOCIAÇÃO ENTRE MACROGLOBULINEMIA DE WALDENSTRÖM E LINFOMA DE HODGKIN CLÁSSICO: RELATO DE CASO
BibTeX
@article{garg2026realworld,
title = {{Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA}},
author = {Mahek Garg and Ambika Satija and Yan Song and Benjamin Meade and James Signorovitch and Shravanthi Gandra},
journal = {Clinical Drug Investigation},
year = {2026},
month = sep,
doi = {10.1007/s40261-026-01592-6},
url = {https://doi.org/10.1007/s40261-026-01592-6},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
AU - Mahek Garg
AU - Ambika Satija
AU - Yan Song
AU - Benjamin Meade
AU - James Signorovitch
AU - Shravanthi Gandra
PY - 2026
DA - 2026/09/19
JO - Clinical Drug Investigation
DO - 10.1007/s40261-026-01592-6
UR - https://doi.org/10.1007/s40261-026-01592-6
AB - Background and Objectives: Indolent non-Hodgkin’s lymphomas (NHL) are associated with relapses necessitating recurrent treatment and lifelong care. However, contemporary real-world evidence of the disease burden among patients with indolent NHLs remains limited. This study describes treatment patterns, healthcare resource use (HRU), and costs among patients with follicular lymphoma (FL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL) in the USA. Methods: Adults with newly diagnosed FL, WM, and MZL were identified in claims data (October 2015−June 2021). The study period spanned from the index date (first observed diagnosis code) until end of continuous enrollment or data availability. Treatment patterns were described during the study period by lines of therapy (LOTs). HRU and costs per-patient-per-month (PPPM) were described overall and by LOTs. Results: This study included 2805 patients with FL, 791 with WM, and 2207 with MZL with a median follow-up of > 20 months each. Bendamustine-based therapies and rituximab monotherapy were most common. In later lines, bendamustine-based therapies declined while rituximab monotherapy and ibrutinib-based therapies increased. Mean all-cause total costs were US $12,402, US $8445, and US $9580 PPPM for patients with FL, WM, and MZL, respectively. Disease-related medical costs constituted > 50% of all-cause total costs, with most hospitalization costs being disease-related. In FL, HRU and costs tended to increase by LOT, driven by FL-related hospitalizations. Trends in HRU and costs across LOTs were less clear for WM and MZL. Conclusions: Our study suggests that indolent NHLs are associated with a significant economic burden that tends to increase across LOTs in FL, highlighting the need for better therapeutic options. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40261-026-01592-6.
SN - 1173-2563
SN - 1179-1918
ER -